Rafferty Asset Management
EPZM

Rafferty Asset Management’s Epizyme, Inc EPZM Stock Holding History

Rafferty Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-238,344
Closed -$1.22M – 1347
2021
Q3 		$1.22M Buy
238,344
+18,246
+8% +$111K 0.01% 762
2021
Q2 		$1.83M Sell
220,098
-52,658
-19% -$444K 0.01% 711
2021
Q1 		$2.38M Buy
272,756
+233,874
+601% +$2.42M 0.02% 577
2020
Q4 		$422K Sell
38,882
-72,688
-65% -$897K ﹤0.01% 720
2020
Q3 		$1.33M Buy
111,570
+74,336
+200% +$996K 0.02% 528
2020
Q2 		$598K Buy
+37,234
New +$650K 0.01% 670
2020
Q1 		– Sell
-47,053
Closed -$1.16M – 856
2019
Q4 		$1.16M Sell
47,053
-83,334
-64% -$1.24M 0.02% 518
2019
Q3 		$1.34M Sell
130,387
-3,950
-3% -$49.8K 0.02% 478
2019
Q2 		$1.69M Buy
134,337
+52,289
+64% +$673K 0.03% 459
2019
Q1 		$1.02M Buy
+82,048
New +$917K 0.02% 543

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Rafferty Asset Management's EPZM Position: Q4 2021 in Review

Rafferty Asset Management sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 238,344 shares — an estimated $1.22M sold.

Rafferty Asset Management first reported a position in EPZM in Q1 2019 and held it in 10 quarters. The position peaked at $2.38M in Q1 2021. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

  • Rafferty Asset Management reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
  • Rafferty Asset Management sold 238,344 Epizyme, Inc shares in Q4 2021, an estimated $1.22M.
  • Rafferty Asset Management first reported a position in Epizyme, Inc in Q1 2019 and held it in 10 quarters.
  • Rafferty Asset Management's Epizyme, Inc position peaked at $2.38M in Q1 2021.
  • 132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on Rafferty Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.